IMVT vs ROIV
IMVT: Immunovant is a clinical-stage biotechnology company developing FcRn-inhibiting therapies to treat patients suffering from debilitating IgG-mediated autoimmune diseases. ROIV: Roivant Sciences is a biopharma company that accelerates drug development through a decentralized model of nimble, independent 'Vant' subsidiaries and proprietary computational tools.
Side-by-side fundamentals
| Metric | IMVT | ROIV | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $30.26 | $34.21 | |
| Market cap | $6.3B | $24.7B | |
| Net margin FY2026, SEC XBRL | n/a | -3629.2% | |
| Operating margin FY2026, SEC XBRL | n/a | -6235.7% | |
| ROE FY2026, SEC XBRL | -59.3% | -5.7% | ROIV higher |
| ROA FY2026, SEC XBRL | -52.8% | -5.3% | ROIV higher |
| Debt / equity as of 2026-09-02 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-09-02 | n/a | -67.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -36.0% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.20 | 0.87 | |
| 1-year return as of 2026-10-08 close | +88.2% | +113.4% | ROIV higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.